Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized authority in cell cycle biology, discovered p53, a key tumor suppressor gene that malfunctions in about two-thirds of human cancers. Cyclacel is using cell cycle control, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.
Under Professor Lane's guidance, our drug discovery and development programs are focused on CDK2/9 isoforms, which operate as key components of the p53 pathway. These efforts resulted in bringing several molecules into clinical development: CYC065, a second-generation CDK inhibitor and CYC140, a highly selective inhibitor of a mitotic pathway enzyme polo-like kinase 1, and CYC682 (Sapacitabine).
Source
